Protection through 2039, ensuring long-term commercial exclusivity.
NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative...
Premier Research to support submission of an Expanded Access Program (EAP) application.
This move positions Hoth to offer compassionate access to HT-001 for cancer patients...
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care
Case Study and Interim Clinical Trial Results Will Be Discussed
NEW YORK, June 5,...